Compare S&P Global Inc (SPGI) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
S&P Global Inc vs State Street SPDR S&P Biotech ETF — how do they compare? S&P Global Inc trades at $404.17 (market cap $118.72B), while State Street SPDR S&P Biotech ETF trades at $153.08 (market cap $10.11B). The key difference: S&P Global Inc is far larger — about 11.7× State Street SPDR S&P Biotech ETF's market cap, and S&P Global Inc pays a 0.96% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold S&P Global Inc for 123 Days and State Street SPDR S&P Biotech ETF for 37 Days on average.
| SPGI | XBI | |
|---|---|---|
Market Cap | $118.72B | $10.11B |
Volume | 1,647,917 | 12,903,266 |
Sector | Financials | Broad Market / Factor |
52-Week High | $517.92 | $169.55 |
52-Week Low | $370.42 | $104.99 |
Typical Hold Time | 123 Days | 37 Days |
Enterprise Value | $130.21B | — |
Dividend Yield | 0.96% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
S&P Global (SPGI) trades at $395.18, down 0.24% on the day, with a bearish technical signal despite strong fundamentals. The company reported robust financials with $15.34B revenue and 30.54% net income margin for 2025, while recent earnings show mixed quarterly performance. Analyst consensus remains strongly bullish with an $509.50 price target, supported by 24 buy ratings. Recent developments include expansion into digital asset risk assessment and AI-driven growth initiatives.
The stock presents a compelling long-term investment opportunity given its strong profitability, market leadership, and analyst support, though technical indicators suggest near-term caution. Key risks include market volatility and execution of growth initiatives, while the 29% upside to consensus target offers significant potential reward for patient investors.
XBI trades at $153.34, up 2.07% today, but faces bearish technical signals with 17 sell indicators versus 4 buys. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from recent M&A activity and positive clinical trial catalysts. Current price sits near resistance at $154, with support at $147.
Biotech sector optimism is growing with cancer vaccine breakthroughs and improved capital access, though XBI's 0.35% expense ratio is higher than broader healthcare ETFs. Key risks include sector volatility and regulatory uncertainty, while analyst consensus remains neutral with 100% hold rating.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About S&P Global Inc
S&P Global provides data and benchmarks to capital and commodity market participants. In 2021 and excluding IHS Markit, S&P Ratings was over 45% of the firm's revenue and over 55% of the firm's operating income. S&P Ratings is the largest credit rating agency in the world. The firm's other segments include Market Intelligence, Indices, and Platts. Market Intelligence provides desktop tools and other data solutions to investment banks, corporations, and other entities. Indices provides benchmarks for financial markets and is monetized through subscriptions, asset-based fees, and transaction-based royalties. Platts provides benchmarks to commodity markets, principally petroleum.
Read more on SPGI →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
